{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:08:33Z","timestamp":1788818913285,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"37","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81630069, 82173046"],"award-info":[{"award-number":["81630069, 82173046"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["242300421093"],"award-info":[{"award-number":["242300421093"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,9,29]]},"DOI":"10.1038\/s41388-026-03923-5","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:04:05Z","timestamp":1785423845000},"page":"3889-3903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["p53 hotspot mutants attenuate CTL-mediated tumor cell killing through a novel ALKBH5-YTHDF3-PD-L1 pathway"],"prefix":"10.1038","volume":"45","author":[{"given":"Zhuan","family":"Ju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9900-3329","authenticated-orcid":false,"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baile","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8854-4672","authenticated-orcid":false,"given":"Angang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6147-1573","authenticated-orcid":false,"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"3923_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/science.1905840","volume":"253","author":"M Hollstein","year":"1991","unstructured":"Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49\u201353.","journal-title":"Science"},{"key":"3923_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc.2017.109","volume":"18","author":"VJN Bykov","year":"2018","unstructured":"Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18:89\u2013102.","journal-title":"Nat Rev Cancer"},{"key":"3923_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","volume":"15","author":"K Sabapathy","year":"2018","unstructured":"Sabapathy K, Lane DP. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Rev Clin Oncol. 2018;15:13\u201330.","journal-title":"Nat Rev Clin Oncol"},{"key":"3923_CR4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/jmcb\/mjaa040","volume":"12","author":"C Zhang","year":"2020","unstructured":"Zhang C, Liu J, Xu D, Zhang T, Hu W, Feng Z. Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol. 2020;12:674\u201387.","journal-title":"J Mol Cell Biol"},{"key":"3923_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/ncb1571","volume":"9","author":"H Song","year":"2007","unstructured":"Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol. 2007;9:573\u201380.","journal-title":"Nat Cell Biol"},{"key":"3923_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.trecan.2019.11.004","volume":"6","author":"Q Tang","year":"2020","unstructured":"Tang Q, Su Z, Gu W, Rustgi AK. Mutant p53 on the Path to Metastasis. Trends Cancer. 2020;6:62\u201373.","journal-title":"Trends Cancer"},{"key":"3923_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3935","volume":"4","author":"C Zhang","year":"2013","unstructured":"Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X, et al. Tumour-associated mutant p53 drives the Warburg effect. Nat Commun. 2013;4:2935.","journal-title":"Nat Commun"},{"key":"3923_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03224-w","volume":"9","author":"T Cooks","year":"2018","unstructured":"Cooks T, Pateras IS, Jenkins LM, Patel KM, Robles AI, Morris J, et al. Mutant p53 cancers reprogram macrophages to tumor-supporting macrophages via exosomal miR-1246. Nat Commun. 2018;9:771.","journal-title":"Nat Commun"},{"key":"3923_CR9","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","volume":"39","author":"M Ghosh","year":"2021","unstructured":"Ghosh M, Saha S, Bettke J, Nagar R, Parrales A, Iwakuma T, et al. Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell. 2021;39:494\u2013508.e495.","journal-title":"Cancer Cell"},{"key":"3923_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41388-023-02886-1","volume":"43","author":"X Dong","year":"2024","unstructured":"Dong X, Li C, Deng C, Liu J, Li D, Zhou T, et al. Regulated secretion of mutant p53 negatively affects T lymphocytes in the tumor microenvironment. Oncogene. 2024;43:92\u2013105.","journal-title":"Oncogene"},{"key":"3923_CR11","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173:945\u201354.","journal-title":"J Immunol"},{"key":"3923_CR12","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027\u201334.","journal-title":"J Exp Med"},{"key":"3923_CR13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793\u2013800.","journal-title":"Nat Med"},{"key":"3923_CR14","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from the host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99:12293\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3923_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","volume":"21","author":"TK Kim","year":"2022","unstructured":"Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat Rev Drug Discov. 2022;21:529\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"3923_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227\u201331.","journal-title":"Science"},{"key":"3923_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ccell.2019.10.001","volume":"36","author":"H Han","year":"2019","unstructured":"Han H, Jain AD, Truica MI, Izquierdo-Ferrer J, Anker JF, Lysy B, et al. Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy. Cancer Cell. 2019;36:483\u201397.e415.","journal-title":"Cancer Cell"},{"key":"3923_CR18","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","volume":"47","author":"MA Coelho","year":"2017","unstructured":"Coelho MA, de Carn\u00e9 Tr\u00e9cesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity. 2017;47:1083\u201399.e1086.","journal-title":"Immunity"},{"key":"3923_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12632","volume":"7","author":"CW Li","year":"2016","unstructured":"Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.","journal-title":"Nat Commun"},{"key":"3923_CR20","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","volume":"30","author":"SO Lim","year":"2016","unstructured":"Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, et al. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016;30:925\u201339.","journal-title":"Cancer Cell"},{"key":"3923_CR21","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.molcel.2021.03.037","volume":"81","author":"X Dai","year":"2021","unstructured":"Dai X, Bu X, Gao Y, Guo J, Hu J, Jiang C, et al. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Mol Cell. 2021;81:2317\u201331.e2316.","journal-title":"Mol Cell"},{"key":"3923_CR22","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41556-020-0562-4","volume":"22","author":"Y Gao","year":"2020","unstructured":"Gao Y, Nihira NT, Bu X, Chu C, Zhang J, Kolodziejczyk A, et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020;22:1064\u201375.","journal-title":"Nat Cell Biol"},{"key":"3923_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29754-y","volume":"13","author":"B Chen","year":"2022","unstructured":"Chen B, Hu J, Hu X, Chen H, Bao R, Zhou Y, et al. DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion. Nat Commun. 2022;13:2059.","journal-title":"Nat Commun"},{"key":"3923_CR24","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1038\/s41418-022-01012-0","volume":"29","author":"J Zhang","year":"2022","unstructured":"Zhang J, Zhang G, Zhang W, Bai L, Wang L, Li T, et al. Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer. Cell Death Differ. 2022;29:2247\u201361.","journal-title":"Cell Death Differ"},{"key":"3923_CR25","doi-asserted-by":"crossref","unstructured":"Lin Q, Liu T, Wang X, Hou G, Xiang Z, Zhang W et al. Long noncoding RNA HITT coordinates with RGS2 to inhibit PD-L1 translation in T cell immunity. J Clin Investig 2023;133.","DOI":"10.1172\/JCI162951"},{"key":"3923_CR26","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1158\/0008-5472.CAN-21-0468","volume":"81","author":"X Qiu","year":"2021","unstructured":"Qiu X, Yang S, Wang S, Wu J, Zheng B, Wang K, et al. M(6)A Demethylase ALKBH5 regulates PD-L1 Expression and tumor immunoenvironment in intrahepatic Cholangiocarcinoma. Cancer Res. 2021;81:4778\u201393.","journal-title":"Cancer Res"},{"key":"3923_CR27","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-21-1323","volume":"82","author":"Z Ni","year":"2022","unstructured":"Ni Z, Sun P, Zheng J, Wu M, Yang C, Cheng M, et al. JNK signaling promotes bladder cancer immune escape by regulating METTL3-mediated m6A modification of PD-L1 mRNA. Cancer Res. 2022;82:1789\u2013802.","journal-title":"Cancer Res"},{"key":"3923_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/ng0593-42","volume":"4","author":"D Dittmer","year":"1993","unstructured":"Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, et al. Gain of function mutations in p53. Nat Genet. 1993;4:42\u20136.","journal-title":"Nat Genet"},{"key":"3923_CR29","doi-asserted-by":"publisher","first-page":"e59567","DOI":"10.1371\/journal.pone.0059567","volume":"8","author":"M Br\u00e1zdov\u00e1","year":"2013","unstructured":"Br\u00e1zdov\u00e1 M, Navr\u00e1tilov\u00e1 L, Tich\u00fd V, N\u011bmcov\u00e1 K, Lexa M, Hrstka R, et al. Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells. PloS One. 2013;8:e59567.","journal-title":"PloS One"},{"key":"3923_CR30","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.cell.2017.05.045","volume":"169","author":"IA Roundtree","year":"2017","unstructured":"Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169:1187\u2013200.","journal-title":"Cell"},{"key":"3923_CR31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nchembio.1432","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10:93\u20135.","journal-title":"Nat Chem Biol"},{"key":"3923_CR32","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nchembio.687","volume":"7","author":"G Jia","year":"2011","unstructured":"Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7:885\u20137.","journal-title":"Nat Chem Biol"},{"key":"3923_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.molcel.2012.10.015","volume":"49","author":"G Zheng","year":"2013","unstructured":"Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49:18\u201329.","journal-title":"Mol Cell"},{"key":"3923_CR34","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1101\/gad.190678.112","volume":"26","author":"WA Freed-Pastor","year":"2012","unstructured":"Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26:1268\u201386.","journal-title":"Genes Dev"},{"key":"3923_CR35","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41580-019-0168-5","volume":"20","author":"S Zaccara","year":"2019","unstructured":"Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20:608\u201324.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3923_CR36","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1093\/nar\/gkw104","volume":"44","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Zeng P, Li YH, Zhang Z, Cui Q. SRAMP: prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features. Nucleic Acids Res. 2016;44:e91.","journal-title":"Nucleic Acids Res"},{"key":"3923_CR37","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1172\/JCI96113","volume":"128","author":"H Lin","year":"2018","unstructured":"Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Investig. 2018;128:805\u201315.","journal-title":"J Clin Investig"},{"key":"3923_CR38","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1172\/JCI96061","volume":"128","author":"H Tang","year":"2018","unstructured":"Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Investig. 2018;128:580\u20138.","journal-title":"J Clin Investig"},{"key":"3923_CR39","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nm863","volume":"9","author":"TJ Curiel","year":"2003","unstructured":"Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9:562\u20137.","journal-title":"Nat Med"},{"key":"3923_CR40","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022;13:974.","journal-title":"Cell Death Dis"},{"key":"3923_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","volume":"6","author":"X Jiang","year":"2021","unstructured":"Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021;6:74.","journal-title":"Signal Transduct Target Ther"},{"key":"3923_CR42","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.molmed.2023.03.005","volume":"29","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yang D, Liu T, Chen J, Yu J, Yi P. N6-methyladenosine-mediated gene regulation and therapeutic implications. Trends Mol Med. 2023;29:454\u201367.","journal-title":"Trends Mol Med"},{"key":"3923_CR43","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1002\/hep.29683","volume":"67","author":"M Chen","year":"2018","unstructured":"Chen M, Wei L, Law CT, Tsang FH, Shen J, Cheng CL, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2018;67:2254\u201370.","journal-title":"Hepatology"},{"key":"3923_CR44","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/hep.28885","volume":"65","author":"JZ Ma","year":"2017","unstructured":"Ma JZ, Yang F, Zhou CC, Liu F, Yuan JH, Wang F, et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6) -methyladenosine-dependent primary MicroRNA processing. Hepatology. 2017;65:529\u201343.","journal-title":"Hepatology"},{"key":"3923_CR45","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/s41556-018-0174-4","volume":"20","author":"J Liu","year":"2018","unstructured":"Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, et al. m(6)A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018;20:1074\u201383.","journal-title":"Nat Cell Biol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03923-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03923-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03923-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:03:11Z","timestamp":1788818591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03923-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":45,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2026,9,29]]}},"alternative-id":["3923"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03923-5","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. All in vivo procedures were carried out in accordance with the guidelines approved by the Animal Experiment Administration Committee of the Fourth Military Medical University (IACUC-20231243). The tissue samples were obtained from Chinese patients diagnosed with breast cancer at Xijing Hospital in Xi\u2019an, China, which is affiliated with the Fourth Military Medical University. This study was reviewed and approved by the Ethics Committee of the Fourth Military Medical University. Written informed consent was obtained from all patients prior to the use of these clinical samples for research purposes, and there was no potential self-selection bias. Sex and gender were not considered in the study, as the primary focus of this study was unrelated to sex or gender.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}